Sun Pharma Q3 FY26 Net Profit Rises 16% to ₹3,369 Crore
Sun Pharma's Q3 FY26 net profit rose 16% to ₹3,369 crore on sales of ₹15,469 crore, up 15.1%. EBITDA increased 23.4% to ₹4,948 crore. The company declared an interim dividend of ₹11 per share. Key launches include Unloxcyt (US) and Ilumya (India), with Semaglutide planned for India.
The results show significant financial growth and strategic product launches, which are material events for investors and the market.
The company reported strong year-on-year growth in net profit, sales, and EBITDA, along with an increased interim dividend, indicating positive financial performance.
Sun Pharmaceutical Industries Limited announced its financial results for the third quarter of FY26, reporting a net profit after tax of ₹33,688 million (₹3,368.8 crore), a 16% increase compared to the same quarter last year. The reported net profit was ₹35,367 million (₹3,536.7 crore) on an adjusted basis, up 9.9% year-on-year. Earnings per share (EPS) for the quarter stood at ₹14.
Total sales for Q3 FY26 reached ₹1,54,691 million (₹15,469.1 crore), marking a 15.1% growth over Q3 FY25. Excluding a milestone income of US$55 million (approximately ₹457 crore) in the rest of the world, the overall sales growth was 14.7%. Gross margin improved to 81% due to a better product mix. EBITDA for the quarter was ₹49,485 million (₹4,948.5 crore), a 23.4% increase year-on-year, with EBITDA margin at 31.9%.
For the first nine months of FY26, sales grew by 11.3% to ₹4,36,604 million (₹43,660.4 crore). The company declared an interim dividend of ₹11 per share for FY26, an increase from ₹10.5 per share in the previous year.
The Global Innovative Medicines business recorded sales of US$423 million, a 14.3% increase. India formulation sales grew by 16.2% to ₹49,986 million (₹4,998.6 crore), with Sun Pharma maintaining its No. 1 market position and an 8.4% market share. The US business saw a marginal 0.6% increase in sales to US$477 million. Emerging markets reported a 21.6% growth in formulation revenues to US$337 million.
Sun Pharma launched Unloxcyt in the US and Ilumya in India during the quarter. The company is also preparing for the launch of Semaglutide in India under the brand names Novel treat and Sematrinity upon patent expiry.
R&D investments for Q3 FY26 stood at ₹8,928 million, representing 5.8% of sales.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.